The use of animals to predict the risk of adverse effects in humans is a long-standing debate within Pharma and also in society at large. Moreover, safety issues leading to clinical attrition remain a problem and a major financial drain on Pharma.
The REPROCELL Blog
When you are considering beginning a project involving iPSC reprogramming, there are several factors to consider when choosing a reprogramming technology and a service provider.
REPROCELL Europe’s CEO, Dr David Bunton, was part of last week's trade mission to China undertaken by the Scottish First Minister, the Rt. Hon. Nicola Sturgeon MSP.
As part of our contract services at REPROCELL, we offer induced pluripotent stem cell (iPSC) characterization by immunocytochemistry (ICC). Planning ICC can be tricky, as it requires careful selection of compatible antibodies and fluorochromes. However, if successful, the results are fantastic! Don’t waste valuable research time performing ICC, and let our experts do the work for you!
Progressive and innovative Pharmaceutical and Biotechnology companies ask themselves several key questions when it comes to Drug Discovery and Development:
• How and where can we be research smarter?
• How can we reduce uncertainty?
• How can we better predict efficacy and safety?
• How can we reduce costs?
One route to making the drug discovery process smarter and more efficient is to use human tissue at one or more stages in the development process.
On Tuesday 20th March 2018 REPROCELL Europe Ltd’s CEO Dr David Bunton appeared in front of the Economy, Jobs and Fair Work Committee at the Scottish Parliament to discuss Scotland’s Economic performance. He was also joined by:
• Dr Diane Harbison, CEO, of Stratified Medicine Scotland
• Claire Mack, CEO, of Scottish Renewables
• Gareth Wynn, Stakeholder and Communications Director, Oil & Gas UK
The pharmaceutical industry suffers from very high rates of clinical failure, because preclinical predictions of efficacy often fail to realize a clinical benefit. In part, this can be attributed to an over-reliance on animal models of efficacy, which often do not fully predict human responses to drugs. Two areas where very few predictive models are available is inflammatory bowel disease (IBD)—which includes ulcerative colitis and Crohn’s disease—and gastrointestinal cancer—specifically cancer of the small intestine and the colon. REPROCELL has set out to solve these challenges by developing new preclinical tests based on human tissues.
RNA Reprogramming is used globally for the generation of integration-free induced pluripotent stem cells (iPSCs) by researchers in biotech, academia, research hospitals and government agencies. This reprogramming method is gaining more and more interest and core labs and biotech companies focusing on regenerative medicine and GMP compatibility are adopting this technology and make it their standard.
3D cell culture. You've heard about it, you've read about it. You're probably daunted by the plethora of techniques available out there, but you want to join the growing number of scientists publishing in the 3D field or you hope it will make your drug discovery pipeline more effective.
But how should you do it? What's the best for your cells?
Many stem cell projects expand to a point where standard culture methods—plates, dishes, flasks, etc.—no longer yield sufficient cells to meet the growing needs for differentiation and regenerative medicine. At this point, larger scale options are required. Traditional bioreactors provide large volume cell culture of liters to hundreds of liters, but they are expensive to buy and expensive to operate. New small scale bioreactors fill the niche between these two extremes perfectly, providing increased cell production over plates or dishes, while being cost-effective to buy and operate.